Benign liver masses are noncancerous growths that arise from various cell types within the liver. They are extremely common — hemangiomas are found in approximately 5% of the general population — and are most often discovered incidentally on imaging performed for an entirely unrelated reason. Most benign liver masses cause no symptoms, require no treatment, and carry an excellent long-term prognosis. The critical clinical challenge is accurately distinguishing them from liver cancer — a task that MRI performs with exceptional accuracy, often eliminating the need for biopsy entirely.
The most important reason to accurately characterize an incidental liver mass is to confidently exclude malignant liver disease — specifically hepatocellular carcinoma (HCC) and metastatic deposits, which can appear superficially similar to benign masses on ultrasound or CT. MRI with its multiparametric capability — T1, T2, diffusion-weighted imaging, and dynamic enhancement — provides the tissue characterization needed to classify virtually every liver mass with high confidence and without biopsy. Patients with known cirrhosis require special attention, as benign regenerative and dysplastic nodules must be distinguished from early HCC using the LI-RADS framework on every liver MRI.
Causes
Varies by mass type.
Each benign liver mass type arises from different cells and has a distinct pathogenesis. Hemangiomas — the most common benign liver mass overall — are vascular malformations composed of large, blood-filled vascular spaces lined by endothelial cells, thought to be present from birth and not true neoplasms. Focal nodular hyperplasia (FNH) is believed to arise from a localized arterial vascular anomaly that causes polyclonal hyperplastic proliferation of normal hepatocytes around a central fibrous scar — it is essentially a vascular reaction rather than a true tumor. Simple hepatic cysts arise from small biliary duct remnants or bile duct microhamartomas and are among the most common incidental liver findings in adults.
Hormonal and metabolic factors.
Hepatic adenomas are the benign liver mass with the most clinically significant associations. They are strongly linked to prolonged oral contraceptive use — the risk is proportional to duration and estrogen dose, with risk increasing 30-fold after more than 9 years of OCP use. Anabolic androgenic steroid use in male athletes and bodybuilders is an important and underappreciated cause. Glycogen storage diseases (particularly Type Ia — von Gierke disease) produce multiple adenomas. Obesity and metabolic syndrome are recognized risk factors for the inflammatory adenoma subtype. Because adenomas are hormonally sensitive, they may enlarge during pregnancy (elevated estrogen) and regress after OCP discontinuation — a behavior that distinguishes them from FNH, which does not change with hormonal status.
Symptoms
The vast majority of benign liver masses are entirely asymptomatic and found incidentally. Larger hemangiomas may cause mild right upper quadrant discomfort or early satiety from stomach compression. Hepatic adenomas — particularly those greater than 5 cm — can rupture and bleed into the peritoneal cavity, causing sudden severe right upper quadrant or generalized abdominal pain that may be accompanied by hemodynamic instability and require emergency surgery. Rupture risk increases substantially with size, with lesions over 5 cm carrying approximately a 20–25% lifetime rupture risk. This life-threatening complication is the primary driver of the surgical threshold for adenoma management. Giant simple cysts occasionally produce symptoms from compression of adjacent structures but rarely require intervention.
Diagnosis
Ultrasound is typically the first study to identify an incidental liver mass — hemangiomas appear as well-defined hyperechoic lesions, FNH as a nearly isoechoic mass, and simple cysts as anechoic fluid collections. However, ultrasound cannot reliably characterize most liver masses, particularly in the setting of fatty liver disease or when the lesion is small, atypical, or in the posterior liver.
An MRI of the abdomen is the most accurate noninvasive characterization tool for liver masses and is the preferred study when a definitive diagnosis is needed. Each benign mass type has characteristic MRI features that allow confident identification. Hemangiomas show marked T2 hyperintensity ("light bulb" appearance on T2) — brighter than all other solid liver masses — and characteristic peripheral nodular enhancement on arterial phase that progressively fills in toward the center on portal venous and delayed phases ("fill-in enhancement"). FNH shows a central stellate scar that is T2-bright and enhances on delayed imaging, with homogeneous arterial hyperenhancement and isointensity on portal venous phase — and isointensity or hyperintensity on hepatobiliary phase when gadoxetate (Eovist/Primovist) contrast is used, reflecting its functioning hepatocytes. Hepatic adenomas show variable T1 signal (often T1-bright from fat or hemorrhage content), variable enhancement, and importantly are hypointense on hepatobiliary phase — which distinguishes them from FNH. Simple cysts are uniformly T2-bright, T1-dark, and show no enhancement. DWI is used to further characterize lesions — benign masses show facilitated diffusion (no restricted DWI), while malignant lesions typically show restricted diffusion (high signal on DWI, low ADC value).
Classification
The most common benign liver masses, each with characteristic MRI appearance and clinical behavior.
- Hemangioma: Most common benign liver mass (5% population prevalence). Vascular malformation with "light bulb" T2 brightness and peripheral nodular fill-in enhancement. Essentially no malignant potential. No treatment or follow-up required when MRI appearance is classic.
- Focal nodular hyperplasia (FNH): Second most common. Polyclonal hyperplastic reaction to a vascular anomaly. Central scar with delayed enhancement is pathognomonic. Hepatobiliary phase hyperintensity on gadoxetate MRI is highly specific. No malignant potential; no treatment required. Does not change with OCP use.
- Hepatic adenoma: Less common but clinically significant. Monoclonal hepatocellular neoplasm. Four subtypes (HNF1-alpha inactivated, inflammatory, beta-catenin activated, unclassified) with different malignant transformation risks — beta-catenin activated subtype has the highest risk. MRI shows fat content (HNF1-alpha subtype) or T2 hyperintensity (inflammatory subtype). Surgical removal recommended for lesions over 5 cm or those that fail to regress after OCP discontinuation.
- Simple hepatic cyst: Very common. T2-bright, T1-dark, no enhancement, no wall thickening. No malignant potential. No follow-up required unless symptomatic or atypical features develop.
- Biliary hamartoma (von Meyenburg complex): Tiny (under 1 cm) T2-bright cystic structures scattered throughout the liver — can be mistaken for metastases on CT or ultrasound, but are confidently identified as benign on MRI. No clinical significance.
Treatments
Treatment depends on mass type, size, symptoms, and specific risk factors. The majority of benign liver masses require no intervention whatsoever.
Observation: Hemangiomas, FNH, and simple cysts confidently diagnosed on MRI require no follow-up imaging in most cases. The diagnosis is definitive and the masses are stable over a lifetime. Reassurance is the primary management. A small adenoma (under 5 cm) that regresses after OCP discontinuation can be monitored with periodic MRI.
Management of hepatic adenoma.
Women with adenomas are advised to discontinue estrogen-containing oral contraceptives, after which adenomas often shrink substantially — typically over 6–12 months — reducing rupture and malignant transformation risk. Adenomas larger than 5 cm that do not regress, adenomas in men (who have higher rates of the beta-catenin activated subtype with greater malignant transformation risk), and adenomas that enlarge during surveillance are recommended for surgical resection. Laparoscopic or open hepatic resection is performed depending on size and location, with curative intent. Radiofrequency ablation or transarterial embolization are alternatives in selected cases.
Treatment of symptomatic lesions.
Symptomatic giant hemangiomas causing significant pain or compression of adjacent structures can be treated with transarterial embolization or surgical resection in rare cases. Giant simple cysts producing symptoms are occasionally treated by laparoscopic deroofing (unroofing) or aspiration with sclerotherapy — though simple aspiration alone has a high recurrence rate.
Adenoma and pregnancy.
Women with adenomas who are planning pregnancy require pre-conception imaging and counseling — enlarging adenomas in pregnancy carry elevated rupture risk. Adenomas over 5 cm should generally be resected before pregnancy. Serial MRI monitoring during pregnancy is recommended for women with smaller adenomas who have not had resection.
Distinguishing from cancer.
The most important role of liver MRI is confident exclusion of malignancy. When MRI findings are classic for a specific benign mass type, biopsy is unnecessary and potentially harmful (biopsy of a hemangioma risks significant hemorrhage). When findings are atypical or indeterminate — particularly in patients with cirrhosis where HCC must always be considered — the LI-RADS system guides management from observation to biopsy or surgical evaluation based on the imaging risk score.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.